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PURPOSE: To investigate enhance-
ment with gadolinium benzyloxypropi-
onictetraacetate (BOPTA) at magnetic
resonance (MR) imaging to detect focal
malignant hepatic lesions.
MATERIALS AND METHODS: A
phase II trial was performed in 34
patients. Gd-BOPTA-enhanced spin-
echo (SE) and gradient-recalled-echo
(GRE) Ti-weighted MR imaging
were performed at 40 and 90 minutes
after intravenous injection of 0.05 and
0.10 mmol/kg Gd-BOPTA.
RESULTS: The percentage of en-
hancement in liver parenchyma was
significantly (P < .05) increased on
GRE Ti-weighted compared with SE
Ti-weighted images at 40 and 90
minutes after injection of the higher
dose and compared with SE and GRE
Ti-weighted images obtained with
the lower dose. The contrast-to-noise
ratio of metastases was significantly
increased on GRE Ti-weighted im-
ages (0.10 mmol/kg) at 90 minutes
compared with precontrast images.
Significantly more small primary me-
tastases were detected on GRE Ti-
weighted images (0.10 mmol/kg) at
90 minutes compared with precon-
trast SE Ti-weighted images.
CONCLUSION: Gd-BOPTA is a safe
hepatobibiary contrast agent that
helps detection of small metastases.
Index terms: Contrast media, 761.12143
Gadolinium, 761.12143 #{149}Liver, MR. 761.12143
Liver neoplasms, MR, 761.33 #{149}Magnetic reso-
nance (MR), contrast agents, 761.12143
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U NENHANCED magnetic resonance
(MR) imaging of focal malignant
hepatic lesions provides little improve-
ment compared with contrast material-
enhanced computed tomography (CT)
with dynamic and/or delayed cvalua-
lion (1-4); moreover, the sensitivity of
MR imaging is inferior to that of CT dur-
ing arterial portography (85%-91%)
(4,5). One approach to improving the
sensitivity of MR imaging to intrahepatic
lesions has been to develop hepatobili-
ary-specific contrast agents (6-14).
Among the hepatobiliary contrast mate-
rials, gadolinium benzyboxypropionictet-
raacetate (BOPTA) showed high hepato-
biliary excretion in in vivo studies in rats
(38.6%) (15,16) and a fairly poor hepato-
biliary excretion in humans (2%-4%)
(17). In a preliminary study of eight
healthy male volunteers, the tolerability
and efficacy of Gd-BOVTA in providing
enhancement in the liver were assessed
(18). In this article, we describe enhance-
ment with Gd-BOPTA in the identifica-
tion of focal hepatic malignancies.
MATERIALS AND METHODS
Contrast Agent
Gd-BOPTA is an octadentate chelate of
gadolinium supplied by Bracco (Milan, Italy).
The synthesis and stability and constant and
relaxivity values ofGd-BOF1 A have been
described previously (15,19,20). The contrast
agent was formulated in two concentrations
(0.25 and 0.5 mmob/L). The density and Os-
molality values of the 0.5-mmol/L solution
are comparable to those for 0.5-mmol/U
gadopentetate dimeglumine (Magnevist;
Schening, Berlin, Germany), whereas the
values of the 0.25-mmol/U solution are ob-
viousby below those of 0.5-mmol/U gado-
pentetate dimeglumine. Injections were
performed outside the magnet room, with
the patients in a comfortable position. The
intravenous administration rate was ap-
proximately 10 mU/mm.
Study Design
The study protocol was designed to as-
sess safety, tolerance, and efficacy of two
different dose levels (0.05 and 0.10 mmob
per kilogram of body weight) of Gd-
BOPTA; this protocol underwent prebimi-
nary approval by the ethics committee of
our institution. Patient exclusion criteria
included age less than 18 years or greater
than 75 years, known reactions after the
administration of gadolinium compounds,
injection with either iodinated contrast
agents during the preceding 48 hours or
of gadolinium compounds in the past 30
days, pregnancy, cardiovascular failure,
severe liver and renal failure, and known
contraindications to the MR imaging cx-
amination.
Thirty-four patients (12 women, 22 men,
aged 25-75 years [mean, 58.6 years ± 12.2
Istandard deviationl]) were selected to par-
ticipate in this study on the basis of focal
hepatic lesions depicted at transabdominal
ultrasonography (US) and/or CT. All CT
examinations were performed with con-
ventionab scanners (DR series; Siemens,
Erlangen, Germany) with 8-mm-thick
contiguous sections, 125 kVp, 230 mA,
and a 3-second scanning time. CT was
performed before and during administra-
tion of 150 mU nonionic contrast media at
a concentration of 350 mg iodine per milli-
liter (Omnipaque 350; Nycomed Imaging,
Oslo, Norway) or 370 mg iodine per milli-
liter (lopamine 370; Bracco), with a dedi-
cated injector (MedRad, Pittsburgh, Pa),
at an injection rate of 2 mU/sec.
MR imaging was performed after injec-
tion of Gd-BOPTA was randomly adminis-
tered at two dose levels. The first group
(16 patients [eight men and eight women,
aged 25-75 years mean, 57.8 years ±
15.2}l) received 0.10 mL/kg of the 0.25
mmol/U Gd-BOPTA solution, which corre-
sponds to a dose of 0.05 mmol/kg. The
second group (18 patients [14 men and
four women, aged 33-72 years mean, 59.3
years ± 9.21]) received 0.10 mL/kg of the
0.5 mmol/L Gd-BOPTA solution, which
corresponds to a dose of 0.10 mmol/kg.
These doses were demonstrated to be
Abbreviations: BOPTA = benzyboxypropi-
onictetraacetate, CI = confidence interval,
C/N = contrast-to-noise ratio, EOB-DTPA =
4(S)-4-(4-ethoxybenzyl)-3,6,9-tris(carboxybato-
methyl)-3,6,9-triazaundecandioic acid-disodium
salt, GRE = gradient-recalled-echo, SE = spin
echo.
Enhancement of Liver Parenchyma on Gd-BOPTA-enhanced MR Images
Imaging Sequence
and Dose
Time after Injection of Gd-BOPTA
40 Minutes 90 Minutes
Median Percentage of Standard Median Percentage of Standard
(mmol/kg) Enhancement Deviation Enhancement Deviation
SE Ti-weighted
0.05 30 45 35 40
0.10 51 36 44 25
GRE TI-weighted
0.05
0.10
Figure 1. Primary malignant tumors (n = 21). Graph depicts median values (on bar) and
standard deviations (above error bar) of the liver-to-lesion C/N on SE (SE) T2 (T2)-weighted
images and on SE and GRE (GE) Ti (Tl)-weighted images obtained before (0) and at 40 (40)
and 90 (90) minutes after administration of the two doses (0.05 [gray bars] and 0.10 [black bars]
mmol/kg) of Gd-BOPTA.
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optimal for liver MR imaging by other in-
vestigatons (18).
Clinical monitoring (physical examination,
blood pressure measurement, electrocardio-
graphy, and blood and urine laboratory tests
focused on potential cardiovascular, hemato-
logic, renal, and hepatobiliary effects) was
performed before and at 24 and 72 hours af-
ten injection of Gd-BOVTA. Any discomfort
and/or laboratory test abnormality reported
within 24 hours after injection of Gd-BOVFA
was followed up to complete recovery.
In all patients, focal malignant lesions of
the liver were confirmed with either fine-
needle liver biopsy (n = 8) on histologic
examination of the resected specimen (n =
26). Primary liver cancers were found in 21
patients (17 with hepatocellubar carci-
noma, four with cholangiocarcinoma).
Among the patients with hepatocelbular
carcinoma, some had either cirrhosis (n =
5) or chronic hepatitis (n = 3). The degree
of differentiation at histologic grading was
poor (n = 6), moderate (71 = 6), and well
differentiated (n = 5). Metastases were
found in 13 patients (coborectal adenocar-
cinoma in six, renal carcinoma in two, car-
cinoid tumor in two, pancreatic neuroen-
docrine tumor in two, and retropenitoneab
sarcoma in one).
All patients underwent intraoperative
US, inspection, and palpation; the findings
at intraoperative US and surgical explora-
tion were the standards of reference for
the qualitative evaluations.
MR Imaging
MR imaging was performed on a 1.5-T
superconducting clinical unit (Magnetom
63 SP; Siemens). The liver was evaluated
with mubtisection acquisition; 10-14 trans-
axial sections (10-mm-thick sections,
2-4-mm gap) were obtained to examine
the whole liver. Matrix values were re-
duced to decrease the acquisition time
(144 x 256-pixel matrix with spin-echo
[SE] sequences, 33 examinations; 160 x
256-pixel matrix with gradient-recalled-
echo [GRE] sequences, 34 examinations;
192 x 256-pixel matrix with SE sequences,
one examination). The field of view was
changed according to the size of each pa-
tient (285 x 380 mm, five patients; 350 x
400 mm, 29 patients).
Before injection of Gd-BOPTA, MR imag-
ing was performed with SE TI-weighted
pulse sequences (repetition time msec/echo
time msec = 350-550/15, with three or four
signals acquired) and T2-weighted (1,800-
2,000/15, 90; with 60#{176}flip angle and two sig-
nals acquired). GRE TI-weighted pulse Se-
quences (95/4, with 80#{176}flip angle and one
signal acquired) were performed in a single
breath-hold interval of 20 seconds or less.
At 40 and 90 minutes after injection of
Gd-BOPTA, MR imaging was performed
with the same SE and GRE TI-weighted
pulse sequences.
Analysis of Images
Quantitative analysis was performed, in
an operator-defined region of interest, of
44
83
the signal intensity and standard devia-
tion of the liver and of a paramagnetic
standard (nickel chloride), which was con-
tamed within two test tubes taped to the
patient’s abdomen. The signal intensity
and standard deviation of the background
were also measured. A region of interest
of the same size was used in all imaging
examinations performed in a patient. In
the liver, the signal intensity was mea-
sured either within the normal paren-
chyma or within the lesion (in the largest
mass if multiple lesions were present). For
measurements within the lesion, the re-
gion of interest was positioned manually
to avoid the necrotic foci; the signal inten-
sity of the NiC1 was also measured in the
same image.
The percentage of enhancement (FE) of
the signal intensity (SI) of the liver after
(post) administration of Gd-BOPTA was
calculated with SI of the liver and NiC1
measured before (pre) and after (post) in-
jection, according to the following formula
(18): PE = [(SIt1ver ,,.,St/SIN1ONS Slhverpre/
SINcipre) : (Slhverpre/SINlCtpre)] x 100.
The contrast-to-noise ratio (C/N), which
reflects the difference in signal intensity
30
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(SI) between the normal liver parenchyma
and the lesion, was calculated according to
the following formula (21): C/N = (SI1 0 -
Slliver)  SDbackg ound noise’ where SD is stan-
dard deviation. The C/Ns of SE and GRE
Tl-weighted images are reported with
positive values to ease the comparison
with the median C/N measured in the
precontrast SE T2-weighted images in
the same series.
Statistical analysis (BMDP Statistical
Software, Los Angeles, Cabif) of the differ-
ences between the two doses of Gd-BOPTA
in the percentage of enhancement at 40 and
90 minutes was performed with the Mann-
Whitney U test. Statistical analysis of the dif-
ferences in the C/Ns before and after admin-
istration of Gd-BOPTA was performed with
the nonparametnic Wilcoxon signed-rank test
for matched pairs, with Bonfernoni correction
for multiple testing.
Qualitative analysis was performed by
dividing the detectable lesions into three
groups, on the basis of their diameter: I
cm or less, 1-3 cm, more than 1-3 cm, and
more than 3 cm. This analysis was per-
formed by two blinded readers (R.C., G.M.)
for both the CT and MR examinations and
0Figure 2. Metastases ( z = 13). Graph depicts median values (on bar) and standard deviations
(above error bar) ofthe liver-to-lesion C/N on SE (SE) T2 (T2)-weighted images and on SE and GRE
(GE) Ti (T1)-weighted images obtained before (0) and at 40 (40) and 90 (90) minutes after adminis-
tration of the two doses (0.05 [gray bars] and 0.10 [black bars] mmol/kg) of Gd-BO VITA.
RESULTS
Figure 3. Renal carcinoma with multiple liver metastases. (a) Contrast-enhanced CT scan.
(b-d) MR images were obtained before injection of0.10 mmol/kg Gd-BOVTA (F #{231}3continues).
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for the two doses of Gd-BOPTA. All pre-
and postcontrast MR images were seen at
the same time by each reader. An initial
interpretation was made independently,
and differences in interpretation were
later resolved by consensus; only the re-
sults of the consensus reading were con-
sidered in the final analysis. The evalua-
tion of conspicuity and border definition
of the lesion was performed before and
after injection of contrast material to as-
sess any improvement.
Qualitative analysis was performed by.
evaluating each multisection set of images
obtained with each imaging sequence be-
fore (SE TI- and T2-weighted and GRE
Ti-weighted) and at 40 and 90 minutes
after injection of Gd-BOPTA (SE and GRE
TI-weighted). The standard of reference
was established by a sonographer (A.P.)
SE SE GE SE GE SE GE and a surgeon (N.N.), who agreed on a
12 Ti Ti Ti Ti Ti Ti single final interpretation of the total
0 0 40 40 90 90 number of lesions detected at intraopera-
tive US during surgical exploration. This
evaluation was performed without sepa-
rating the detected lesions according to
their size, owing to the difficulty of assess-
ing the precise size of the lesions at intra-
operative US or surgical inspection and
palpation. Statistical analysis of the differ-
ence in the number of lesions counted on
the various images obtained before and
after administration of Gd-BOPTA, with
both doses, was performed with the non-
parametric Wilcoxon signed-rank test for
matched pairs, with Bonferroni correction
for multiple testing. A P value less than .05
was considered statistically significant.
The same test was also used to assess the
difference in the number of lesions de-
tected with Gd-BOPTA-enhanced MR im-
aging, contrast-enhanced CT, and the
standard of reference. Sensitivity levels
with confidence intervals (CIs) were also
calculated at contrast-enhanced CT and
MR imaging before and after administra-
tion of Gd-BOPTA.
Patient Monitoring
No adverse side effects were ob-
served during intravenous adminis-
tration of Gd-BOPTA. A transient in-
crease in blood pressure of 8.6 mm Hg
plus or minus 6.9 and in pulse rate of
10.7 beats per minute plus or minus
7.4 immediately after the injection
was observed that was believed to be
caused by the injection; the increases
did not persist, did not necessitate
medical treatment, or were not con-
sidered serious by the investigators.
One female patient with metastatic
renal carcinoma, who received 0.10
mmol/kg Gd-BOPTA, experienced
one episode of mild diarrhea 24 hours
after injection that completely sub-
sided within 72 hours after injection.
No clinically important changes were
observed at electrocardiography or in
the blood and urine laboratory tests.
e. f.
g. h.
Figure 3 (continued). (e-h) MR images were obtained at 40 minutes (in e, f) and 90 minutes (in g,
h) after injection of0.lO mmol/kg Gd-BOVTA. The images were obtained with conventional SE T2-
weighted (in b) and Ti-weighted (in c, e, g) sequences and with a fast GRE Tl-weighted sequence
(in d, f, h). The enhancement in the liver parenchyma, the C/N, and the number of the lesions (an-
rowheads) that could be detected with confidence increased on f and h.
Quantitative Analysis
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Percentage of enhancement-The me-
dian values of the percentage of en-
hancement in the liver parenchyma af-
ter administration of the two doses of
contrast material (0.05 and 0.10 mmob/
kg) on Ti-weighted SE and GRE images
obtained at 40 minutes and 90 minutes
after injection are reported in the Table.
The highest percentages of enhance-
ment in the hepatic tissue have been
achieved with the higher dose of con-
trast material on GRE Ti-weighted im-
ages obtained at 40 (83% ± 36) and 90
minutes (86% ± 35). The difference in
percentage of enhancement at each time
was not significant. Moreover, the per-
centage of enhancement on GRE Ti-
weighted images obtained with the
higher dose was significantly superior to
the percentage of enhancement on SE
Ti-weighted images obtained at both
time points with either dose of contrast
agent. On only GRE Ti-weighted im-
ages was the difference significant (P <
.Oi) in the percentage of enhancement
depicted on images obtained at both
time points with both the lower dose
(44% ± 30 at 40 minutes, 47% ± 59 at 90
minutes) and the higher dose (83% ± 36
at 40 minutes, 86% ± 35 at 90 minutes).
C/Ns.-The median C/Ns before and
after administration of Gd-BOPTA are
reported in Figures 1 and 2. As shown in
Figure i, the highest median C/N mea-
sured in the series of primary malignant
lesions were achieved with the SE Ti-
weighted sequence at 40 minutes (19 ±
21) with the lower dose and at 90 mm-
utes (i9 ± 14) with the higher dose; at
40 minutes in images obtained with the
same sequence, the C/N in the images
obtained with the higher dose (8.8 ±
11.0) was bow compared with the value
at 40 minutes in images obtained with
the bower dose (19 ± 21). No significant
difference was observed in the C/Ns on
pre- and postcontrast SE and GRE im-
ages or on images obtained with the two
doses. The C/Ns measured on precon-
trast SE T2-weighted images were 13 ±
18 (0.05 mmol/kg dose) and 13 ± ii
(0.10 mmol/kg dose). No significant dif-
ference in C/Ns was observed on pre-
contrast SE T2-weighted images and
postcontrast SE and GRE Ti-weighted
images.
In Figure 2, the highest median
C/Ns measured in this series of liver
metastases were achieved on post-
contrast SE Ti-weighted images ob-
tamed at 90 minutes with 0.05 and
0_io mmob/kg Gd-BOPTA (20 ± i6
and 20 ± 14, respectively) and on
GRE Ti-weighted images obtained
at 90 minutes with 0.iO mmob/kg Gd-
BOPTA (30 ± i9). A significant differ-
ence in C/N was observed between
GRE Ti-weighted images obtained
before and at 90 minutes after injec-
tion of 0.10 mmol/kg Gd-BOPTA. The
C/Ns measured on precontrast SE
T2-weighted images were 40.0 plus on
minus 9.7 (0.05 mmob/kg dose) and 17
plus or minus 22 (0.iO mmol/kg dose).
No significant difference was observed
between the C/Ns on precontrast SE
T2-weighted images and on the GRE
Ti-weighted images obtained 90 mm-
utes after intravenous administration
of 0.10 mmol/kg Gd-BOPTA.
Qualitative Analysis
Improved conspicuity and defini-
tion of the lesion border was observed
by both readers and was more pro-
nounced in metastases (Fig 3) than in
primary malignant lesions (Fig 4). Fig-
ures 5 and 6 show the number of be-
sions identified on contrast-enhanced
CT scans and on pre- and postcon-
trast MR images, divided into the
three size categories, as well as the
sensitivity values.
Priniari inali#{231}na iicit’s.-Fon primary
malignancies (n = 21), the maximum
number of lesions 1 cm or less in di-
ameter (ii = 37) (Fig 5) was detected
on postcontrast GRE TI-weighted
images at 40 minutes. The maximum
number of lesions more than 1 cm to 3
cm in diameter (n = 16) was detected
on precontrast SE Ti-weighted im-
ages. The maximum number of be-
sions more than 3 cm in diameter (ii =
19) was demonstrated on postcontrast
a. b.
c. d.
Figure 4. Cholangiocarcinoma of the fourth segment. (a) Contrast-enhanced CT scan.
(b-d) MR images were obtained before injection of0.10 mmol/kg Gd-BOPTA (Fig 4 continues).
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GRE Ti-weighted images obtained at
90 minutes. No significant difference
was observed in the number of be-
sions i cm or less in diameter that
were detected on images obtained
with any of the unenhanced or con-
trast-enhanced MR imaging se-
quences or Ofl contrast-enhanced CT
scans. In a comparison of images ob-
tamed with all the unenhanced or
contrast-enhanced MR imaging se-
quences, the difference between the
total number of primary lesions de-
tected on MR images compared with
the standard of reference (ii = 96) was
significant for only SE Ti-weighted
images obtained before and at 40 mm-
utes after injection of Gd-BOPTA. The
sensitivity values and the CIs in-
cluded the following: CT (0.68 [95%
CI, 0.59, 0.77]); unenhanced MR imag-
ing, SE T2-weighted (0.45 [95% CI,
0.36, 0.54), SE Ti-weighted (0.32 [95%
CI, 0.23, 0.4iJ), and GRE Ti-weighted
(0.43 [95% CI, 0.34, 0.52]); contrast-
enhanced MR imaging, at 40 minutes
after injection, SE Ti-weighted (0.41
[95% CI, 0.32, 0.50]), GRE Ti-weighted
(0.71 [95% CI, 0.63, 0.79]), and at 90 mm-
utes after injection, SE TI-weighted (0.52
[95% CI, 0.43, 0.6i]) and GRE TI-
weighted (0.72 [95% CI, 0.64, 0.80]).
Mefastases.-In the series of metas-
tases (;i = i3), the maximum number
of metastases not more than i cm in
diameter (Fig 6) was detected on post-
contrast GRE TI-weighted MR images
obtained 90 minutes after injection of
Gd-BOPTA (n = 158). The maximum
number of lesions more than i cm to 3
cm in diameter was detected on post-
contrast SE Ti-weighted MR images
obtained 90 minutes after injection of
Gd-BOPTA (;i = 91). Lesions more
than 3 cm in diameter (ii = 15) were
detected equably on unenhanced and
contrast-enhanced images obtained
with all pulse sequences except on
postcontrast SE Ti-weighted images
obtained at both 40 and 90 minutes
after injection of Gd-BOPTA (ti = 14).
For lesions not more than 1 cm in di-
ameter, the difference in the number
of lesions detected was significant
between only postcontrast GRE Ti-
weighted images obtained at 90 mm-
utes and pnecontrast SE Ti-weighted
images. In a comparison of the num-
ber of metastases depicted on images
obtained with all unenhanced and
contrast-enhanced MR imaging se-
quences and the standard of refer-
ence (n = 285), the difference was
significant for only precontrast SE Ti-
weighted images. The sensitivity values
with CIs were the following: CT (0.52
[95% CI, 0.47, 0.57]); unenhanced MR
imaging, SE T2-weighted (0.56 [95% CI,
0.51, 0.61]), SE Ti-weighted (0.38 [95%
CI, 0.33, 0.43]), and GRE Ti-weighted
(0.48 [95% Cl, 0.43, 0.53]); contrast-en-
hanced MR imaging, at 40 minutes, SE
Ti-weighted imaging (0.44 [95% CI, 0.39,
0.49]) and GRE Ti-weighted imaging
(0.84 [95% CI, 0.80, 0.88]), and at 90 mm-
utes, SE Ti-weighted (0.62 [95% CI, 0.57,
0.67]) and GRE Ti-weighted (0.89 [95%
CI, 0.86, 0.92]).
DISCUSSION
Among the water-soluble paramag-
netic contrast agents that influence
the Ti relaxation time, those targeted
to the hepatocytes are currently un-
der investigation (22). Gd-BOPTA is
excreted through both the urinary
and hepatobiliary routes. The benzy-
boxymethyl group represents the mo-
lecular handle that enables Gd-BOVTA
to be recognized by a carrier-mediated
transport system and thus taken up by
the hepatocyte; the biliary excretion of
Gd-BOPTA was shown to be a saturable
process and its hepatic clearance to be
inhibited by bromosulfophtalein (i8,23).
In the current study we confirmed
an increased enhancement in the liver
parenchyma after administra tion of
Gd-BOPTA, which had already been
observed by Vogl et al in healthy vol-
unteens (18), that is due to the active
transport mechanism of the contrast
agent within the hepatocyte. A dose
of 0.10 mmol/kg demonstrated sig-
nificantly greater enhancement on
GRE images obtained at both 40 and
90 minutes after injection. Similar val-
ues of liver enhancement with doses
higher than 0.10 mmol/kg have been
demonstrated previously in animals
(16) and in humans (18). It is not
known so far if the lack of further in-
crease in the enhancement with doses
e. f.
g. h.
Figure 4 (continued). (e-h) MR images were obtained at 40 minutes (in e, f) and 90 minutes
(in g, h) after injection of 0.10 mmol/kg Gd-BOPTA. The images were obtained with conven-
tional SE T2-weighted (in b) and TI-weighted (in c, e, g) sequences and with a fast GRE Ti-
weighted sequence (in d, f, h). The enhancement in the liver parenchyma increased but the
C/N of the lesion did not significantly increase on e-h.
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higher than 0.10 mmol/kg is due to
saturation of the mechanism of the
carrier-mediated cellular uptake or to
an increased T2 effect (7,18).
Other positive paramagnetic contrast
agents besides Gd-BOFTA accumulate
within the liver tissue, including manga-
fodipir trisodium (Mn-DPDP) (6) and
gadopentetate dimeglumine covalently
linked to the lipophilic ethoxybenzyl
moiety 4(S)-4-(4-ethoxybenzyb)-3,6,9-
tris(carboxybatomethyl)-3,6,9-triaza-
undecandioic acid-disodium salt
(Gd-EOB-DTPA) (12). Additionally,
these hepatobiliary paramagnetic
contrast materials increase the relaxiv-
ity of the hepatic tissue and thus the
sensitivity of MR imaging for detec-
tion of intrahepatic tumors. The
higher rebaxivity of the hepatic tissue
after administration of hepatobiliary-
specific contrast agents is probably
due to either an increased microvis-
cosity inside the hepatocyte or to some
transient interaction with intracellular
proteins (22). Therefore, the surprising
relaxivity of Gd-BOVTA within hepatic
tissue (30 [mmob/L . sec]’), which is
higher than the relaxivity of mangafo-
dipir trisodium (21.7 [mmol/L . secj’)
and ofGd-EOB-DTPA (16.6 [mmol/L 
secJ l) in the same target tissue, may be
related to the high macromolecular
binding, which could compensate for
the lower hepatocellular uptake of
Gd-BOPTA compared with the signifi-
cantly higher uptake of mangafodipir
trisodium and Gd-EOB-DTPA (i5,22).
Primary malignant lesions showed
a wide variation in C/N after adminis-
tration of Gd-BOPTA. No significant
difference was found in the C/N of
primary lesions before and after ad-
ministration of Gd-BOVTA. This varia-
tion may be due to the interindividuab
variability (22) in liver function caused
by age and liver diseases (hepatitis, cir-
rhosis, tumor spread), which may re-
duce the amount of contrast material
uptake by the hepatocytes. It is likely
that the saturation of hepatocytic uptake
is reached more rapidly with the higher
dose (0.iO mmol/kg) of Gd-BOPTA.
As to the behavior of the lesion, tu-
mor enhancement is affected not only
by the early and short vascular and
interstitial phase of Gd-BOPTA but
also by the pooling of contrast mate-
nab in the central, less vascubarized
area of the tumor, where the rate of
washout is decreased (24). In addi-
tion, the tumors in the four cases of
cholangiocarcinoma were large (di-
ameter, 6-10 cm); thus, it is likely that
the delayed washout of Gd-BOPTA in
these lesions reduced the difference
in signal intensity compared with that
of the surrounding liver tissue, which
decreased the C/N. Also, some well-
differentiated hepatocellular carcino-
mas retain some hepatocelbular func-
tion; thus they presumably may take
up hepatospecific contrast agents, as
has been seen with mangafodipir tri-
sodium (ii,25) and Gd-EOB-DTPA
(26). In our series, the five well-differ-
entiated hepatocebbular carcinomas
may have exhibited this hepatocyte-
like activity.
Finally, the presence of fat or para-
magnetic ions (27) within some types
of small hepatocellular carcinomas in-
creases the signal intensity of the lesion
on Ti-weighted images; thus, on pre-
and postcontrast images some hepato-
cellular carcinomas may have higher
signal intensity than the surrounding
normal liver tissue. Consequently after
administration of Gd-BOPTA, the in-
creased signal intensity in the peritu-
moral liver parenchyma, as a result of
uptake of the contrast agent, may re-
duce the difference in the signal inten-
sity of the lesion and the normal tissue,
and the C/N may be decreased.
The number of primary mabignan-
cies identified that were 1 cm or less
in diameter did not significantly in-
crease on Gd-BOPTA-enhanced MR
images compared with contrast-en-
hanced CT and unenhanced MR im-
ages. Moreover, the difference in the
total number of primary lesions iden-
tified on MR images compared with
the standard of reference was signifi-
cant on only SE Ti-weighted images
obtained before and at 40 minutes
after administration of Gd-BOPTA;
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U)Ca
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Figure 5. Primary malignant tumors (ii = 21). Graph depicts the number of lesions according to size. Sensitivity values (over black bars) refer
to the total number of lesions (ii = 96) identified at intraoperative US and surgical exploration (standard of reference). Data are presented for
lesions more than 1 cm to 3 cm and more than 3 cm in diameter, respectively, throughout. The number of lesions depicted on contrast-en-
hanced CT (CT) scans was 35, 13, and iS, respectively. The number oflesions depicted on precontrast SE (SE) T2 (T2)-weighted images was ii,
16, and 17, respectively; on precontrast SE Ti (T1)-weighted images was seven, nine, and 15, respectively; and on precontrast GRE (GE) TI-
weighted images was 10, 15, and 17, respectively. The number oflesions depicted on Gd-BOPTA-enhanced SE Ti-weighted images at 40 (40)
minutes was 18, seven, and 15, respectively, and at 90 (90) minutes was 25, nine, and i6, respectively; on Gd-BOPTA-enhanced GRE TI-
weighted images at 40 minutes was 37, i5, and i7, respectively, and at 90 minutes was 36, 15, and 19, respectively.
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Figure 6. Metastases (ii = 13). Graph depicts the number of the lesions identified according to their size. Sensitivity values (over black bars)
refer to the total number of lesions (n = 285) identified with intraoperative US and surgical exploration (standard of reference). Data are pre-
sented for lesions more than 1 cm to 3 cm or more than 3 cm in diameter, respectively, throughout. The number of lesions depicted on con-
trast-enhanced CT (CT) scans was 56, 79, and 15, respectively. The number of lesions depicted on precontrast SE (SE) T2 (T2)-weighted images
was 68, 79, and 15, respectively; on precontrast SE Ti (Tl)-wcighted images was 24, 72, and 15, respectively; and on precontrast GRE (GE) Ti-
weighted images was 38, 85, and 15, respectively. The number of lesions depicted on Gd-BOPTA-enhanced SE Ti-weighted images at 40 (40)
minutes was 41, 72, and 14, respectively, and at 90 (90) minutes was 74, 91, and i4, respectively; on Gd-BOPTA-enhanced GRE TI-weighted
images at 40 minutes was 141, 84, and 15, respectively, and at 90 minutes was 158, 83, and 15, respectively.
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therefore, Gd-BOPTA may not im-
prove the sensitivity of detection of
primary malignancies. Sensitivity val-
ues increased the most for contrast-
enhanced GRE TI-weighted imaging
performed at 90 minutes, although
the difference compared with the sen-
sitivity of contrast-enhanced CT was
only slight.
The changes in C/Ns were different
for liver metastases, because these be-
sions have no specific cellular uptake of
the contrast agent. In the bate intervals
after administration of Gd-BOPTA,
therefore, metastases did not show any
important enhancement in most cases,
especially not on contrast-enhanced
GRE Ti-weighted images. Lesion con-
spicuity was best on these images com-
pared with those obtained with the
other sequences, thanks to the great re-
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duction in breath- and peristalsis-related
artifacts, which improved the identifica-
tion of lesions i cm or less in diameter
(Fig 3). Sensitivity values increased the
most on contrast-enhanced GRE Ti-
weighted images obtained at 40 and 90
minutes.
Qualitative analysis in our study
indicated that sensitivity improved
for Gd-BOPTA-enhanced GRE Ti-
weighted images, but our study was
limited by the lack of independent
read-out sessions for pre- and post-
contrast MR images. On the other
hand, quantitative analysis in our study
indicated that results with GRE Ti-
weighted images obtained with the
higher dose of Gd-BOVTA at 90 minutes
were significantly superior to results
with the unenhanced images obtained
with the same sequence. The imaging
window provided by Gd-BOVTA, be-
tween 40 and 90 minutes, is much
longer than the imaging window pro-
vided by gadopentetate dimeglumine,
which is limited to the early phase of the
vascular and interstitial distribution of
the contrast agent (2 minutes) (28).
In conclusion, results in this study
indicate that intravenously adminis-
tered Gd-BOPTA is well tolerated by
patients. Gd-BOPTA provides a pro-
longed plateau of signal intensity en-
hancement within the liver paren-
chyma, which is greatest with the
higher dose of 0.iO mmol/kg, owing
to its hepatobibiary specificity. These
results are encouraging and optimis-
tic, but more data on the tolerance for
and performance of Gd-BOPTA will
be available from other clinical trials
that are currently under way. #{149}
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